Novel ferrocenyl-containing N-Acetyl-2-pyrazolines inhibit in vitro angiogenesis and human lung cancer growth by interfering with F-Actin stress fiber polimeryzation

Drug and Chemical Toxicology

Volumn 36, Issue 4, 2013, Pages 484-495

  Bostancioǧlu, Rakibe Beklem ^a   Demirel, Seda ^b   Turgut Cin, Günseli ^b   Koparal, Ayse Tansu ^a  

^a ANADOLU UNIVERSITY   (Turkey)

^b AKDENIZ UNIVERSITY   (Turkey)

Author keywords

2 Pyrazoline; Antiangiogenic; Antitumoral; Apoptotic; Cytotoxic; F Actin stress fiber; Ferrocene

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CISPLATIN; F ACTIN; FERROCENE DERIVATIVE; N ACETYL 3,5 DIFERROCENYL 2 PYRAZOLINE; N ACETYL 5 FERROCENYL 3 (2 FURYL) 2 PYRAZOLINE; N ACETYL 5 FERROCENYL 3 (2 THIENYL) 2 PYRAZOLINE; N ACETYL 5 FERROCENYL 3 PHENYL 2 PYRAZOLINE; PYRAZOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ACTIN FILAMENT; ACTIN POLYMERIZATION; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CAPILLARY; COLONY FORMATION; COLONY FORMING UNIT; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG NON SMALL CELL CANCER; STRESS FIBER; UMBILICAL VEIN ENDOTHELIAL CELL;

ACTINS; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; COLLAGEN; COLONY-FORMING UNITS ASSAY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; FERROUS COMPOUNDS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INDOLES; LAMININ; LUNG NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; POLYMERIZATION; PROTEOGLYCANS; PYRAZOLES; TETRAZOLIUM SALTS; THIAZOLES; THIOPHENES;

EID: 84883345181     PISSN: 01480545     EISSN: 15256014     Source Type: Journal    
DOI: 10.3109/01480545.2013.776579     Document Type: Article

References (65)

1. Aepfelbacher M, Essler M, Huber E, et al. (1997). Bacterial toxins block endothelial wound repair. Evidence that Rho GTPases control cytoskeletal reorganization in migrating endothelial cells. Arterioscler Thromb Vasc Biol 17:1623-9.
2. Alderden RA, Mellor HR, Modok S, et al. (2006). Cytotoxic efficacy of an anthraquinone linked platinum anticancer drug. Biochem Pharmacol 71:1136-45.
3. Ansari FL, Nazira S, Noureenb H, Mirzab B. (2005). Combinatorial synthesis and antibacterial evaluation of an indexed chalcone library. Chem Biodivers 2:1656-64.
4. Banday AH, Mira BP, Lonea IH, et al. (2010). Studies on novel D-ring substituted steroidal pyrazolines as potential anticancer agents. Steroids 75:805-9.
5. Bhat TA, Singh RP. (2008). Tumor angiogenesis a potential target in cancer chemoprevention. Food Chem Toxicol 46:1334-45.
6. Bijman MNA, van Berkel MPA, van Nieuw Amerongen GP, Boven E. (2008). Interference with actin dynamics is superior to disturbance of microtubule function in the inhibition of human ovarian cancer cell motility. Biochem Pharmacol 76:707-16.
7. Bostancioglu RB, I̧sik K, Genc H, et al. (2012a). Studies on the cytotoxic, apoptotic, and antitumoral effects of Au(III), Pt(II) complexes of 1,10-phenanthroline on V79 379A and A549 cell lines. J Enzym Inhib Med Chem 27, 458-66.
8. Bostancioglu RB, Kürkçüoglu M, Ba̧ser KHC, Koparal AT. (2012b). Assessment of anti-Angiogenic and anti-tumoral potentials of Origanum onites L. essential oil. Food Chem Toxicol 50:2002-8.
9. Budakoti A, Abid M, Azam A. (2006). Synthesis and antiamoebic activity of new 1-N-substituted thiocarbamoyl-3,5-diphenyl-2-pyrazoline derivatives and their Pd(II) complexes. Eur J Med Chem 41: 63-70.
10. Chavain N, Biot C. (2010). Organometallic complexes: new tools for chemotherapy. Curr Med Chem 17:2729-45.
11. Chen HH, Zhou HJ, Fang X. (2003). Inhibition of human cancer cell line growth and human umbilical vein endothelial cell angiogenesis by artemisinin derivatives in vitro. Pharmacol Res 48:231-6.
12. Chou JJ, Li H, Salvesen GS, et al. (1999). Solution structure of BID, an intracellular amplifier of apoptotic signaling. Cell 96:615-24.
13. Congiu C, Onnis V, Vesci L, et al. (2010). Synthesis and in vitro antitumor activity of new 4,5-dihydropyrazole derivatives. Bioorgan Med Chem 18:6238-48.
14. Csámpai A, Györfi AZ, Túrós Gy. I, Sohar P. (2009). Application of Biginelli reaction to the synthesis of ferrocenylpyrimidones and [3]-ferrocenophane-containing pyrimido[4,5-d] pyrimidinediones. Organomet Chem 694:3667-73.
15. D'Amore PA, Thompson RW. (1987). Mechanisms of angiogenesis. Annu Rev Physiol 49:453-64.
16. D'amato RJ, Loughnan MS, Flynn E, Folkman J. (1994). Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91:4082-5.
17. Durand PM, Coetzer TL. (2008). Utility of computational methods to identify the apoptosis machinery in unicellular eukaryotes. Bioinform Biol Insights 2:101-17.
18. Fang J, Jin Z, Li Z, Liu W. (2003). Synthesis, structure, and antibacterial activities of novel ferrocenyl-containing 1-phenyl-3-ferrocenyl-4- triazolyl-5-Aryl-dihydropyrazole derivatives. J Organomet Chem 674:1-9.
19. Folkman J. (1971). Tumor angiogenesis: therapeutic applications. New Engl J Med 285:1182-6.
20. Folkman J. (1995). Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1:27-30.
21. Gasser G, Metzler-Nolte N. (2012). The potential of organometallic complexes in medicinal chemistry. Curr Opin Chem Biol 16:84-91.
22. Gasser G, Ott I, Metzler-Nolte N. (2011). Organometallic anticancer compounds. J Med Chem 54:3-25.
23. Griffioen AW, Molema G. (2000). Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol Rev 52:237-68.
24. Gu Y, Zhang HY, Zhang HJ, et al. (2006). 8-Cloro-Adenosine inhibits growth at least partly by interfering with actin polimeryzation in cultured human lung cancer cells. Biochem Pharm 72:541-50.
25. Havrylyuk D, Zimenkovsky B, Vasylenko O, et al. (2009). Synthesis of novel thiazolone-based compounds containing pyrazoline moiety and evaluation of their anticancer activity. Eur J Med Chem 44: 1396-404.
26. Huang L-J, Shih M-L, Chen H-S, et al. (2006). Synthesis of N2-(substituted benzyl)-3-(4-methylphenyl)indazoles as novel anti-Angiogenic agents. Bioorg Med Chem 14:528-36.
27. Hueso-Falcón I, Giron N, Velasco P, et al. (2010). Synthesis and induction of apoptosis signaling pathway of ent-kaurane derivatives. Bioorgan Med Chem 18:1724-35.
28. Ihde DC. (1992). Chemotherapy of lung cancer. N Engl J Med 327: 1434-41.
29. Jeong TS, Kim KS, An S, et al. (2004). Novel 3,5-diaryl pyrazolines as human acyl-CoA:cholesterol acyltransferase inhibitors. Bioorg Med Chem Lett 14:2715-17.
30. Karaday N, Turgut Cin G, Demirel S, et al. (2009). 1-Acetyl-5-ferrocenyl- 3-phenyl-2-pyrazoline. Acta Cryst Sec E E65:m127-8.
31. Klimova T, Klimova EI, Martinez Garcia M, et al. (2001). Stereoselectivity of formation of polycyclic ferrocenyl-4,5-dihydropyrazoles based on E-And Z-s-cis-A,b-enones. J Organomet Chem 628:107-13.
32. Koparal AT, Ulus G, Zeytinoglu M, et al. (2010). Angiogenesis inhibition by a lichen compound olivetoric acid. Phytother Res 24: 754-8.
33. Krill D, Madden J, Huncik K, Moeller PD. (2010). Induced thyme product prevents VEGF-induced migration in human umbilical vein endothelial cells. Biochem Bioph Res Commun 403:275-81.
34. Li W, Chan S, Guo DJ, et al. (2009). Water extract of Rheum officinale Baill. Induces apoptosis in human lung adenocarcinoma A549 and human breast cancer MCF-7 cell lines. J Ethnopharmacol 124:251-6.
35. Li Y, Sun W-G, Liu H-K, et al. (2011). g-Tocotrienol inhibits angiogenesis of human umbilical vein endothelia cell induced by cancer cell. J Nutr Biochem 22:1127-36.
36. Liu J, Liu T, Dai H, et al. (2006). Synthesis, structure, and biological activity studies of 2-[(1H-1,2,4-triazol-1-yl)methyl]-1-Aryl)-3-ferrocenyl prop-2-en-1-one derivatives. Appl Organomet Chem 20:610-14.
37. Mazur I, Anhlan D, Mitzner D, et al. (2008). The proapoptotic influenza A virus protein PB1-F2 regulates viral polymerase activity by interaction with the PB1 protein. Cell Microbiol 10:1140-52.
38. Moon DO, Kim MO, Nam TJ, et al. (2010). Pectenotoxin-2 induces G2/M phase cell cycle arrest in human breast cancer cells via ATM and Chk1/2-mediated phosphorylation of cdc25C. Oncol Rep 24:271-6.
39. Mossman T. (1983). Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Met 65:55-63.
40. Niu J, Mo Q, Wang H, et al. (2012). Invasion inhibition by a MEK inhibitor correlates with the actin-based cytoskeleton in lung cancer A549 cells. Biochem Biop Res Commun 422:80-8.
41. Ornelas C. (2011). Application of ferrocene and its derivatives in cancer research. New J Chem 35:1973-85.
42. Ouchi N, Kobayashi H, Kiahara S, et al. (2004). Adiponectin stimulates angiogenesis by promoting cross-talk between AMP-Activated protein kinase and Akt signaling in endothelial cell. J Biol Chem 279:1304-9.
43. Özdemir Z, Kandilci HB, Gümü ̧sel B, et al. 2007a), Synthesis and studies on antidepressant and anticonvulsant activities of some 3-(2-furyl)-pyrazoline derivatives. Eur J Med Chem, 42, 373-9.
44. Özdemir A, Turan-Zitouni G, Kaplanckl ZA, et al. 2007b), Synthesis of some 4-Arylidenamino-4H-1,2,4-triazole-3-thiols and their antituberculosis activity. Eur J Med Chem, 42, 403-9.
45. Pardakhty A, Varshosaz J, Rouholamini A. (2007). In vitro study of polyoxyethylene alkyl ether niosomes for delivery of insulin. Int J Pharm 328:130-41.
46. Patra M, Gasser G, Metzler-Nolte N. (2012). Small organometallic compounds as antibacterial agents. Dalton Trans 41:6350-8.
47. Raju H, Chandrappa S, Ramakrishna MK, et al. (2010). Synthesis, characterization, and anti-Angiogenic effects of novel 5-Amino pyrazole derivatives on Ehrlich ascites tumor [EAT] cells in-vivo. J Cancer Ther 1:1-9.
48. Roux C, Biot C. (2012). Ferrocene-based antimalarials. Future Med Chem 4:783-97.
49. Rubin LL, Hall DE, Porter S, et al. (1991). A cell culture model of the blood-brain barrier. J Cell Biol 115:1725-35.
50. Shaharyar M, Abdullah MM, Bakht MA, Majeed J. (2010). Pyrazoline bearing benzimidazoles: search for anticancer agent. Eur J Med Chem 45:114-19.
51. Top S, Dauer B, Vaissermann J, Jaouen G. (1997). Facile route to ferrocifen, 1-[4-(2-dimethylaminoethoxy)]-1-(phenyl-2-ferrocenylbut-1-ene), first organometallic analogue of tamoxifen, by the McMurry reaction. J Organomet Chem 541:355-61.
52. Top S, Tang J, Vessieres A, et al. (1996). Ferrocenyl hydroxytamoxifen: a prototype for a new range of oestradiol receptor site-directed cytotoxics. Chem Commun 82:955-6.
53. Top S, Vessieres A, Cabestaing C, et al. (2001). Studies on organometallic selective estrogen receptor modulators. (SERMs) Dual activity in the hydroxy-ferrocifen series. J Organomet Chem 637:500-6.
54. Top S, Vessieres A, Leclercq G, et al. (2003). Synthesis, biochemical properties and molecular modelling studies of organometallic specific estrogen receptor modulators (SERMs), the ferrocifens and hydroxyferrocifens: evidence for an antiproliferative effect of hydroxyferrocifens on both hormone-dependent and hormone-independent breast cancer cell lines. J Chem Eur 9:5223-36.
55. Tsai AC, Pan SL, Liao CH, et al. (2010). Moscatilin, a bibenzyl derivative from the India orchid Dendrobrium loddigesii, suppresses tumor angiogenesis and growth in vitro and in vivo. Cancer Lett 292: 163-70.
56. Turgut Cin G, Demirel S, Karaday N, Büyükgüngör O. (2008). 1-Acetyl-5-ferrocenyl-3-phenyl-2-pyrazoline. Acta Cryst Sec E E64: m514-5.
57. Turgut Cin G, Demirel S, Çakc A. (2011). Synthesis of novel ferrocenyl-containing pyrazolo[4,3-c]quinolines. J Organomet Chem 696:613-21.
58. Turgut Cin G, Demirel S, Çakc A, et al. (2012). Synthesis, crystal structure and thermal properties of N-Acetyl-3-(2-furyl)-5-ferrocenyl-2- pyrazoline and N-Acetyl-3-(2-thienyl)-5-ferrocenyl-2-pyrazoline. J Chem Crystallogr 42:372-80.
59. van Zandwijk N, Giaccone G. (1996). Treatment of metastatic non-small cell lung cancer. Curr Opin Oncol 8:120-5.
60. Wu X, Tiekink ER, Kostetski I, et al. (2006). Antiplasmodial activity of ferrocenyl chalcones: investigations into the role of ferrocene. Eur J Pharm Sci 17:175-87.
61. Xie YS, Pan X-H, Zhao B-X, et al. (2008). Synthesis, structure characterization, and preliminary biological evaluation of novel 5-Alkyl-2-ferrocenyl-6,7-dihydropyrazolo[1,5-A]pyrazin-4(5H)-one derivatives. J Organomet Chem 693:1367-74.
62. Xie Y-S, Zhao H-L, Su H, et al. (2010). Synthesis, single-crystal characterization, and preliminary biological evaluation of novel ferrocenyl pyrazolo[1,5-A]pyrazin-4(5H)-one derivatives. Eur J Med Chem 45:210-8.
63. Zora M, Görmen M. (2007). Synthesis of ferrocenyl pyrazoles by the reaction of (2-formyl-1-chlorovinyl)ferrocene with hydrazines. J Organomet Chem 692:5026-32.
64. Zora M, Velioglu Ö. (2008). Synthesis of ferrocenyl quinolines. J Organomet Chem 693:2159-62.
65. Zsoldos-Mády V, Csámpai A, Szabó R, et al. (2006). Synthesis, structure, and in vitro antitumor activity of some glycoside derivatives of ferrocenyl-chalcones and ferrocenyl-pyrazolines. Chem Med Chem 1:1119-25.